Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis

Bioiberica

Status and phase: Completed; Phase 4

Conditions: Psoriasis; Osteoarthritis; Joint Diseases; Skin Diseases; Muskuloskeletal Diseases

Treatments: Drug: Placebo; Drug: Chondroitin sulphate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00669123

CS/IV/PSO/ART

Details and patient eligibility

About

The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.

Enrollment: 126 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary knee OA according to ACR criteria;
• OA of radiological stages 1 to 3 according to Kellgren-Lawrence;
• VAS of pain ≥30;
• PASI ≥ 5.

Exclusion criteria

• Known allergy to chondroitin sulphate;
• Other bone and articular diseases such as chondrocalcinosis, Paget's disease, rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's disease;
• Patients with skin conditions that could interfere in the clinical trial evaluation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

126 participants in 2 patient groups, including a placebo group

2

Placebo Comparator group

Treatment:

Drug: Placebo

1

Experimental group

Description:

Chondroitin sulphate

Treatment:

Drug: Chondroitin sulphate